The AR dependent cell cycle: mechanisms and cancer relevance
- PMID: 21782001
- PMCID: PMC3641823
- DOI: 10.1016/j.mce.2011.06.033
The AR dependent cell cycle: mechanisms and cancer relevance
Abstract
Prostate cancer cells are exquisitely dependent on androgen receptor (AR) activity for proliferation and survival. As these functions are critical targets of therapeutic intervention for human disease, it is imperative to delineate the mechanisms by which AR engages the cell cycle engine. More than a decade of research has revealed that elegant intercommunication between AR and the cell cycle machinery governs receptor-dependent cellular proliferation, and that perturbations in this process occur frequently in human disease. Here, AR-cell cycle interplay and associated cancer relevance will be reviewed.
Copyright © 2011. Published by Elsevier Ireland Ltd.
Figures


Similar articles
-
Role of androgen receptor in prostate cancer cell cycle regulation: interaction with cell cycle regulatory proteins and enzymes of DNA synthesis.Curr Protein Pept Sci. 2010 Sep;11(6):451-8. doi: 10.2174/138920310791824075. Curr Protein Pept Sci. 2010. PMID: 20491624 Review.
-
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15085-90. doi: 10.1073/pnas.0603057103. Epub 2006 Oct 2. Proc Natl Acad Sci U S A. 2006. PMID: 17015840 Free PMC article.
-
A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression.J Biol Chem. 2012 Jul 13;287(29):24832-43. doi: 10.1074/jbc.M112.370783. Epub 2012 May 31. J Biol Chem. 2012. PMID: 22654108 Free PMC article.
-
Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.Prostate. 2005 Dec 1;65(4):287-98. doi: 10.1002/pros.20285. Prostate. 2005. PMID: 16015608
-
Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer.J Cell Biochem. 2006 Aug 15;98(6):1408-23. doi: 10.1002/jcb.20927. J Cell Biochem. 2006. PMID: 16619263 Review.
Cited by
-
MAP3K7 Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of CHD1.Mol Cancer Res. 2021 Jul;19(7):1123-1136. doi: 10.1158/1541-7786.MCR-20-0913. Epub 2021 Apr 12. Mol Cancer Res. 2021. PMID: 33846123 Free PMC article.
-
Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium.J Exp Clin Cancer Res. 2024 Jul 17;43(1):194. doi: 10.1186/s13046-024-03125-5. J Exp Clin Cancer Res. 2024. PMID: 39014480 Free PMC article.
-
Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor.Cell Death Dis. 2017 Feb 2;8(2):e2585. doi: 10.1038/cddis.2016.477. Cell Death Dis. 2017. PMID: 28151478 Free PMC article.
-
Androgen and Androgen Receptor as Enhancers of M2 Macrophage Polarization in Allergic Lung Inflammation.J Immunol. 2018 Nov 15;201(10):2923-2933. doi: 10.4049/jimmunol.1800352. Epub 2018 Oct 10. J Immunol. 2018. PMID: 30305328 Free PMC article.
-
Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice.Oncotarget. 2015 Mar 20;6(8):6136-50. doi: 10.18632/oncotarget.3346. Oncotarget. 2015. PMID: 25704883 Free PMC article.
References
-
- Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M, Kosma VM. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate. 1999;39:8–15. - PubMed
-
- Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 1999;91:1869–1876. - PubMed
-
- Alt JR, Gladden AB, Diehl JA. P21(Cip1) Promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J Biol Chem. 2002;277:8517–8523. - PubMed
-
- Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563–4571. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials